


Bioaccessibility of isoflavone aglycones from soy food is enhanced by bile salts during *in vitro* digestion

Kelly R. Walsh[†], Yu Chu Zhang[‡], Yael Vodovotz[‡], Steven J. Schwartz^{†,‡}, Mark L. Failla^{†*}

ABSTRACT

Isoflavone (IFN) aglycones, but not glucosides, are preferentially transferred across the apical membrane of enterocytes despite their relative insolubility in an aqueous milieu. Here we investigated the impact of bile extract (BE) on bioaccessibility of IFN from a soy food. Soy bread was subjected to simulated oral, gastric, and small intestinal digestion. The aqueous (bioaccessible) fraction was isolated from digesta by centrifugation and analyzed by HPLC. IFN glucosides and aglycones were stable during simulated digestion with recoveries from soy bread exceeding 98%. Partitioning of aglycones, but not glucosides or malonyl glucosides, into the aqueous fraction was affected by BE concentration during simulated small intestinal digestion. Transfer of aglycones into the aqueous fraction at standard BE concentration (2.4 mg/mL) was < 65%. Omission of BE resulted in absence of genistein and < 4% of total daidzein, glycitein, and acetylgenistein present in the aqueous fraction. With BE at 4.8 mg/mL, 102, 54, 120, and 79 % of daidzein, genistein, glycitein, and acetylgenistein, respectively, partitioned into the aqueous fraction. Results suggest that micellization is required for optimal IFN aglycone bioaccessibility in the small intestine, and that bioavailability of IFN from foods will exceed that of supplements due to enhanced bile secretion in response to fat and protein ingestion.

INTRODUCTION



Digestion and Absorption of Soy Isoflavonoids In The Upper GI Tract




Table 1. Chemical Speciation of Isoflavonoids

Daidzein Family	Genistein Family	Glycitein Family

SPECIFIC AIM 1 Are isoflavonoids from soy bread stable during simulated oral, gastric, and small intestinal phases of digestion?

MATERIALS & METHODS


In Vitro Digestion (6,7)

Oral Phase
Chew bread 10 X, collect in beaker
Rinse mouth with saline, expel into beaker
Stir at 23°C, 5 min
Dilute with saline
Homogenize

Gastric Phase
Adjust pH to 2.0
Add pepsin (2.0 mg/mL)
Incubate: 85 RPM, 37°C, 1 h

Small Intestinal Phase
Adjust pH to 6.0
Add bile extract (2.4 mg/mL), pancreatin (0.4 mg/mL), and pancreatic lipase (0.2 mg/mL)
Adjust pH to 6.9
Incubate: 85 RPM, 37°C, 2 h


Analysis of Isoflavonoids in Starting and Digested Soy Bread (8)



HPLC SYSTEM		
Column	3.9 x 150 mm Nova-Pak C18	
Separation	Waters 2695 Separations Module	
Detector	Waters 2996 Photodiode Array (PDA)	
Software	Empower	
HPLC CONDITIONS		
Flow Rate	0.6 mL/min	
Injection Volume	10 µL	
Run Time	50 min	
PDA	210 – 400 nm (λ max = 260 nm)	
Column Temp.	25°C	
SOLVENT GRADIENT		
Time (min)	% A (1% Acetic Acid)	% B (Acetonitrile)
0	85	15
5	85	15
36	71	29
44	65	35
45	85	15

RESULTS


Figure 1. Reverse-phase HPLC analysis of isoflavonoids in starting and digested soy bread.



*Digesta: Soy bread sample that was subjected to simulated oral, gastric, and small intestinal digestion.


SPECIFIC AIM 2 Does low solubility of isoflavone aglycones necessitate micellization for optimal bioaccessibility in the small intestine?

MATERIALS & METHODS



RESULTS



Figure 3. Reverse-phase HPLC analysis of the aqueous fraction of digesta following *in vitro* digestion with varying bile concentration.



Note that the area under the curve for daidzein (gold circle), genistein (red circle), glycitein (teal circle) and acetylgenistein (brown circle) in the aqueous fraction increases as the concentration of bile extract present during the small intestinal phase of digestion is increased.


Figure 2. Isoflavonoids are stable during simulated oral, gastric, and small intestinal digestion.

The amount of daidzein, genistein, and acetylgenistein in the aqueous (bioaccessible) fraction of digesta was significantly ($P < 0.01$) less than that in the digesta.



* Significantly different ($P < 0.01$) from the starting soy bread meal. Data are means \pm SE.

Figure 4. Bile enhances partitioning of daidzein, glycitein, acetylgenistein, and genistein into the aqueous (bioaccessible) fraction of the digesta. Partitioning of conjugates of daidzein and glycitein were not affected by the concentration of bile extract during simulated small intestinal digestion.



Data are mean percentages \pm SEM. Means within a group that do not share a common letter above bars differ significantly ($P < 0.01$) from one another as determined by one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc comparison of statistical significance.

SUMMARY

In general, isoflavonoids from soy bread were stable during simulated oral, gastric, and small intestinal phases of digestion (figures 1 & 2).

A considerable percentage of isoflavonoid aglycones and acetylgenistein in the digesta were absent from the aqueous bioaccessible fraction (figures 1 & 2).

Micellization during the small intestinal phase of simulated digestion appears to enhance the bioaccessibility of isoflavonoid aglycones and acetylgenistein (figures 3 & 4).

Partitioning of malonylglycitein and the glucoside conjugates of daidzein was independent of the bile extract content during the small intestinal phase of simulated digestion (figures 3 & 4).

CONCLUSION

Bioavailability of isoflavonoids from foods containing fat and protein may exceed that of isoflavonoid supplements consumed without food due to enhanced bile secretion.

ACKNOWLEDGEMENTS

Funds for this research were provided in part by USDA IFAFS, the Ohio Agriculture Research and Development Center, and the OSU Comprehensive Cancer Center.

REFERENCES

- Setchell, K.D. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. *Am. J. Clin. Nutr.* 1998, 68(suppl), 1333S-1346S.
- Setchell, K.D. Soy isoflavones-benefits and risks from nature's selective estrogen receptor modulators (SERMs). *J. Am. Coll. Nutr.* 2001, 20(5), 354S-362S.
- Birt, D.F.; Hendrich, S.; Wang, W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. *Pharmac. Ther.* 2001, 90, 157-177.
- Fournier, D.B.; Erdman, J.W.; Gordon, G.B. Soy, its components, and cancer prevention: a review of the *in vitro*, animal and human data. *Cancer Epidemiol. Biomarkers Prev.* 1998, 7(11), 1055-65.
- Tanumihardjo, S.A. Factors influencing the conversion of carotenoids to retinol: Bioavailability to bioconversion to bioefficacy. *Int. J. Vitam. Res.* 2002, 72(1), 40-45.
- Muir, J.G.; O'Dea K. Measurement of resistant starch: factors affecting the amount of starch escaping digestion *in vitro*. *Am. J. Clin. Nutr.* 1992, 56, 123-127.
- Garrett, D. A.; Failla, M. L.; Sarama, R. J.; Development of an *in vitro* digestion method to assess carotenoid bioavailability from meals. *J. Agric. Food Chem.* 1999, 47, 4301-4309.
- Wang, H.J.; Murphy, P.A. Isoflavone content in commercial soybean foods. *J. Agric. Food Chem.* 1994, 42, 1666-1673.